灵活的科学

2023年4月4日

灵活的可吸收的设备带来了新的见解胃健康。分享:Healthtech启动灵活科学已经筹集了270万美元CAD解锁关键肠道健康数据。敏捷开发了一个可摄取的设备的形式胶囊能够收集的样本以前不折不扣的小肠。“这是第一次我们能下到最深的地区和在广泛的范围内。”——萨拜娜Bruehlmann、灵活融合基金领导参与第一次引发企业的超额认购轮,校友企业,喜悦伙伴,她VC, StartupTNT,和TNT资本。圆还包括后续资助计划合作伙伴,包括BoxOne企业、阈值的影响,蓝天股票、uce儿童健康和健康基金,和一些不为人知的天使。灵活的首席执行官和创始人萨拜娜Bruehlmann说使用设备的新资金将用于构建数据集来证明公司的技术。灵活的胶囊临床验证收集被污染的样本最深的小肠和先前难以接近的区域。Bruehlmann描述的胶囊BetaKit看起来像鱼油丸。“这是第一次我们能下到最深的地区和在广泛的范围内,”她说。 Bruehlmann likens the sample to a blood test. The capsule travels through the small intestine just like a small piece of food. The shell of the capsule opens, revealing large ports that wick in fluid from the small intestine, and can also sample stools. Once the capsule has passed through an individual’s system, it is retrieved and can be sent back to Nimble just like a stool sample. “Like a blood test, we need the actual fluid in our hands to run the different tests,” Bruehlmann noted. Once the user sends the capsule back, Nimble removes the intestinal fluid and then is able to perform a number of analyses on the sample. “We’re trying to take a very broad strategy of getting capsules into the hands of the brightest researchers, and the companies that are on the leading edge,” Bruehlmann said. The startup ultimately hopes to sell both the capsules as well as the data it gathers to the medical industry. “We are excited to back Nimble as it seeks to leverage its novel technology to generate first-in-class datasets that will illuminate the small intestinal microbiome, and unlock the development of a new category of microbiome-based diagnostics and therapeutics,” said Ivneet Bhullar, principal at Fusion Fund. With its recent funding, Nimble has come out of stealth mode after three years. Joseph Wang co-founded the startup and invented the capsule. He is a Chinese national who came to Canada over seven years ago to pursue his interest in wearable and ingestible medical device research and development. Nimble took part in the Creative Destruction Labs Rockies 2019, where Wang was introduced to Bruehlmann, who previously had over 18 years of experience with early stage medical device commercialization. “I had been through the paces, and had some things to bring to the table,” Bruehlmann said. “I was ready to jump out and do my own thing, and start again at the beginning of a company.” Currently, Nimble has a staff of nine, but hopes to expand to 16 in the next year. Nimble believes it is the only commercial startup doing what it does, but Bruehlmann acknowledged that a lot of academic groups are focused on the research as well. The National Institute of Health in the United States put out a call for proposals for researchers to develop a way to get at small intestinal material, saying the scientific community needs this. While the space active, Bruehlmann said Nimble’s focus has been to keep its technology as simple and effective as possible. “It’s really about low-cost, broad access, but high-quality samples,” she said. Feature image Nimble Science.